ArticleLeukemia research reports2020

Efficacy of ruxolitinib in a patient with myelodysplastic/myeloproliferative neoplasm unclassifiable and co-mutated JAK2, SF3B1 and TP53.

Qian Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.